SABS – sab biotherapeutics, inc. (US:NASDAQ)

News

SAB BIO to Participate in Upcoming Investor Conferences
SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf [Yahoo! Finance]
SAB BIO to Participate in Upcoming Investor Conferences
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com